Shop – BEHEMOTH LABZ

Adalank

Zeeshan Tariq — Thu, 01 Oct 2026 17:05:45 +0000

Buy Adalank Online

Adalank is marketed as a stabilized or modified analogue of Selank, a synthetic peptide originally investigated for anxiolytic and neuroactive effects. However, the public scientific record for Adalank itself is extremely limited, and claims about its properties are largely extrapolated from Selank rather than supported by dedicated Adalank studies.

Product Information

Unlike Selank, which has a defined peptide sequence and a published research record, Adalank does not currently have a clearly documented independent sequence, pharmacokinetic profile, or clinical-trial literature under that name. A 2026 database review reported no PubMed records specifically indexed under “Adalank.”

How It Works

A validated mechanism for Adalank has not been established. Proposed mechanisms are generally borrowed from Selank research, including potential effects on neurotrophic and neurotransmitter-related pathways, but these mechanisms should not be assumed to apply identically to an analogue whose structure has not been independently characterized.

POTENTIAL BENEFITS

1. Selank-Analogue Research

Adalank is primarily relevant to research examining whether structural modification of Selank can alter stability, duration, or biological activity. This is currently a proposed research rationale rather than a clinically demonstrated advantage.

2. Neurotrophic Research

Selank research has investigated neurotrophin-related signaling, including BDNF pathways. These findings provide background for Adalank research, but direct evidence for Adalank itself remains limited.

3. Cognitive Research

Modified Selank analogues are of interest in research into attention, memory, stress response, and cognitive signaling. However, these areas remain substantially better documented for Selank than for Adalank.

4. Peptide-Stability Research

The primary claimed distinction of Adalank is improved stability compared with Selank. Because independent stability studies are not publicly established, this remains an important area for future characterization.

Dosage

There is no established human dosage for Adalank. Some commercial sources publish microgram-level protocols, but these are vendor claims rather than validated clinical dosing data. The absence of dedicated human trials means Selank dosing should not simply be transferred to Adalank.

Side Effects

A reliable human safety profile has not been established for Adalank. The lack of dedicated clinical studies means its tolerability, pharmacokinetics, metabolism, and long-term effects remain uncertain.

References

Note: BehemothLabz does not sell this product. Purchase links on this page may direct to third-party suppliers through affiliate links.

Cagrilintide + Semaglutide (CagriSema)

Zeeshan Tariq — Thu, 01 Oct 2026 17:05:42 +0000

Buy Cagrilintide + Semaglutide (CagriSema) Online

CagriSema combines cagrilintide, an amylin analogue, with semaglutide, a GLP-1 receptor agonist. The combination is designed to influence complementary pathways involved in appetite, glucose regulation, and body-weight control.

Product Information

Cagrilintide acts on amylin receptors, while semaglutide activates GLP-1 receptors. Clinical development has evaluated the two compounds as a once-weekly fixed-dose combination, including phase 3 studies in obesity and type 2 diabetes.

How It Works

Semaglutide activates GLP-1 receptors involved in appetite and glucose regulation, while cagrilintide mimics amylin signaling involved in satiety and post-meal metabolic control. Their complementary mechanisms are intended to produce combined effects on energy intake and glucose metabolism.

POTENTIAL BENEFITS

1. Weight-Management Research

Phase 3 clinical research has demonstrated substantial body-weight reductions with once-weekly CagriSema. In REIMAGINE 1, the 2.4 mg + 2.4 mg combination produced a mean relative body-weight reduction of 13.8% at week 40 in adults with early-stage type 2 diabetes.

2. Glycemic-Control Research

CagriSema has been evaluated in people with type 2 diabetes, including participants receiving basal insulin. Recent phase 3 research demonstrated improved HbA1c compared with placebo and relevant comparator groups.

3. Appetite & Satiety Research

GLP-1 and amylin signaling both influence food intake and satiety. Combining these pathways provides a research model for studying multiple physiological signals controlling energy consumption.

4. Dual-Pathway Metabolic Research

CagriSema is particularly relevant to research examining whether complementary incretin and amylin signaling can produce broader metabolic effects than either pathway alone.

Dosage

Clinical trials have evaluated CagriSema using 1.0 mg + 1.0 mg and 2.4 mg + 2.4 mg weekly target doses, with dose escalation used during treatment. These are investigational trial regimens and should not be treated as an established general-use dosing protocol.

Side Effects

Gastrointestinal adverse events are among the most frequently reported effects in clinical studies. Recent phase 3 research reported nausea and other gastrointestinal disorders among the most common adverse events, consistent with the pharmacology of GLP-1 receptor agonism and previous cagrilintide data.

References

Note: BehemothLabz does not sell this product. Purchase links on this page may direct to third-party suppliers through affiliate links.

Tirzepatide

Zeeshan Tariq — Thu, 01 Oct 2026 17:05:39 +0000

Buy Tirzepatide Online

Tirzepatide is a long-acting GIP and GLP-1 receptor agonist developed for metabolic disease. It has extensive clinical evidence in type 2 diabetes and obesity and is marketed in the United States as Mounjaro and Zepbound for different indications.

Product Information

Tirzepatide is a modified peptide engineered for prolonged activity after once-weekly administration. Its dual incretin mechanism combines GIP receptor activation with GLP-1 receptor activation, affecting insulin secretion, glucagon regulation, appetite, and energy balance.

How It Works

Tirzepatide activates both GIP and GLP-1 receptors. These pathways enhance glucose-dependent insulin secretion and influence appetite and energy intake, while the combined signaling produces broad metabolic effects.

POTENTIAL BENEFITS

1. Blood-Glucose Research

Tirzepatide produces substantial reductions in HbA1c in clinical trials involving type 2 diabetes. Its dual incretin activity contributes to improved glucose regulation.

2. Weight-Management Research

Large clinical studies have demonstrated significant body-weight reductions in adults with obesity or overweight. This has made tirzepatide a major subject of modern metabolic research.

3. Insulin-Sensitivity Research

GIP and GLP-1 signaling influence insulin secretion and metabolic regulation. Tirzepatide has therefore been investigated extensively for changes in insulin sensitivity and broader cardiometabolic markers.

4. Metabolic-Disease Research

Tirzepatide research extends beyond glucose and body weight into cardiovascular risk factors, fatty liver disease, sleep apnea, and other obesity-associated conditions.

Dosage

For Zepbound, the current U.S. prescribing information starts at 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly. Further increases can be made in 2.5 mg increments at intervals of at least 4 weeks, with maintenance doses of 5, 10, or 15 mg once weekly depending on indication and tolerability.

Side Effects

The most common adverse effects include nausea, diarrhea, vomiting, constipation, and abdominal discomfort. Important warnings include pancreatitis, gallbladder disease, acute kidney injury associated with severe gastrointestinal reactions, and the boxed warning concerning thyroid C-cell tumors observed in rodents.

References

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Semaglutide

Zeeshan Tariq — Thu, 01 Oct 2026 17:05:36 +0000

Buy Semaglutide Online

Semaglutide is a long-acting GLP-1 receptor agonist with extensive clinical evidence in type 2 diabetes, obesity, cardiovascular risk reduction, and related metabolic conditions.

Product Information

Semaglutide is structurally related to human GLP-1 and has approximately 94% sequence homology with human GLP-1. It activates GLP-1 receptors involved in glucose-dependent insulin secretion, appetite regulation, gastric emptying, and energy balance.

How It Works

Semaglutide activates GLP-1 receptors in the pancreas, brain, gastrointestinal tract, and other tissues. It increases glucose-dependent insulin secretion, reduces glucagon secretion when glucose is elevated, slows gastric emptying, and influences appetite-regulating pathways.

POTENTIAL BENEFITS

1. Blood-Glucose Research

Semaglutide has demonstrated clinically meaningful reductions in blood glucose and HbA1c in people with type 2 diabetes. Its glucose-dependent mechanism helps explain its established role in diabetes treatment.

2. Weight-Management Research

Large clinical trials have demonstrated substantial body-weight reductions with once-weekly semaglutide alongside lifestyle intervention. The compound is therefore extensively studied in obesity and metabolic research.

3. Cardiovascular Research

Semaglutide has been studied in cardiovascular-risk populations, with clinical evidence supporting cardiovascular risk reduction in specified patient groups. Current U.S. labeling includes cardiovascular-risk indications for selected populations.

4. Metabolic Research

Beyond weight and glucose, semaglutide has been investigated in areas including cardiovascular disease, kidney outcomes, and metabolic liver disease. Its broad research profile reflects the wide physiological distribution of GLP-1 signaling.

Dosage

For the current U.S. injectable Wegovy formulation, treatment is initiated at 0.25 mg once weekly for 4 weeks, followed by gradual escalation. The labeled maintenance dosage for most weight-management indications is 2.4 mg once weekly, with 1.7 mg available as an alternative maintenance dose in appropriate circumstances.

Side Effects

The most common adverse effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Important labeled warnings include acute pancreatitis, gallbladder disease, and the contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN2.

References

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Telmisartan

Zeeshan Tariq — Thu, 01 Oct 2026 17:05:33 +0000

Buy Telmisartan Online

Telmisartan is an angiotensin II receptor blocker (ARB) used clinically to treat hypertension and, in appropriate patients, reduce cardiovascular risk. It has also been investigated for metabolic and PPAR-related effects beyond conventional blood-pressure control.

Product Information

Telmisartan selectively blocks the angiotensin II AT1 receptor, preventing angiotensin II from producing vasoconstriction and aldosterone-related effects. It has a long elimination half-life, supporting once-daily administration in standard clinical use.

How It Works

Telmisartan blocks AT1 receptors in the renin-angiotensin system. This reduces vasoconstriction and aldosterone-mediated sodium retention, lowering vascular resistance and blood pressure.

POTENTIAL BENEFITS

1. Blood-Pressure Research

Telmisartan is well established as an antihypertensive medication. Controlled clinical studies have demonstrated reductions in blood pressure through blockade of angiotensin II signaling.

2. Cardiovascular Research

By reducing blood pressure and blocking AT1 signaling, telmisartan has been studied extensively in cardiovascular-risk populations. Its clinical research extends beyond simple blood-pressure measurements.

3. Renin-Angiotensin Research

Telmisartan is an important pharmacological tool for studying the renin-angiotensin-aldosterone system. AT1 receptor blockade allows researchers to examine downstream cardiovascular and renal effects of angiotensin II.

4. Metabolic Research

Telmisartan has also attracted interest because of reported interactions with metabolic pathways, including partial PPAR-γ activity. These effects have been investigated separately from its established ARB mechanism.

Dosage

For hypertension, the current U.S. labeling lists 40 mg once daily as the usual starting dose, with a usual range of 40–80 mg once daily. For cardiovascular-risk reduction in the labeled indication, 80 mg once daily is specified. Dosage must be individualized according to indication and clinical response.

Side Effects

Common concerns include dizziness, hypotension, and changes in kidney function or potassium levels. Telmisartan carries an important pregnancy warning because drugs acting on the renin-angiotensin system can cause fetal injury.

References

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Trevogrumab

Zeeshan Tariq — Thu, 01 Oct 2026 17:05:31 +0000

Buy Trevogrumab Online

Trevogrumab is a monoclonal antibody designed to inhibit myostatin (GDF-8). It has been investigated as a strategy for preserving skeletal muscle during weight loss and for modifying muscle-related outcomes.

Product Information

Trevogrumab is an investigational anti-myostatin antibody developed by Regeneron. By binding myostatin, it is intended to reduce signaling that normally restrains skeletal muscle growth. Clinical development has increasingly examined its use alongside obesity therapies.

How It Works

Trevogrumab binds myostatin and prevents it from activating its normal signaling pathway. Because myostatin acts as a negative regulator of skeletal muscle growth, blocking the pathway can alter muscle mass and composition.

POTENTIAL BENEFITS

1. Myostatin Research

Trevogrumab provides a targeted way to investigate the biological role of myostatin in humans. Blocking GDF-8 signaling allows researchers to study how this pathway influences muscle maintenance.

2. Muscle-Preservation Research

Recent clinical development has focused on whether myostatin inhibition can preserve lean mass during substantial weight loss. A 2026 clinical report evaluated trevogrumab alongside semaglutide in adults with obesity.

3. Body-Composition Research

The compound is relevant to research distinguishing total weight reduction from changes in lean and fat mass. This is particularly important in metabolic research where body composition is an important endpoint.

4. Muscle-Regeneration Research

Myostatin signaling is closely involved in skeletal-muscle growth and remodeling. Trevogrumab therefore provides a research tool for examining whether targeted inhibition can modify muscle physiology.

Dosage

Trevogrumab remains investigational, so there is no established clinical dosage for general use. Recent clinical research has evaluated doses including 75 mg, while other trial programs have investigated different dose levels and schedules. These remain study-specific exposures rather than an established treatment regimen.

Side Effects

The safety profile remains under clinical investigation. As an antibody targeting a major muscle-growth pathway, potential effects must be evaluated through controlled trials rather than inferred solely from preclinical myostatin research.

References

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

PRL-8-53

Zeeshan Tariq — Thu, 01 Oct 2026 17:05:28 +0000

Buy PRL-8-53 Online

PRL-8-53 is a synthetic research compound that attracted interest because of its potential effects on memory and learning. Its evidence base is unusually limited, with one small controlled human study published in 1978 and little subsequent clinical research.

Product Information

The original human investigation evaluated PRL-8-53 in a double-blind, placebo-controlled design using a verbal-learning and memory task. The study reported improved retention of verbal information, while visual reaction time and motor control did not show significant changes. No substantial modern clinical development program followed.

How It Works

The precise mechanism of PRL-8-53 has never been adequately established. Early pharmacological research proposed effects involving cholinergic and catecholaminergic systems, but modern mechanistic and clinical evidence remains sparse.

POTENTIAL BENEFITS

1. Memory Research

The strongest human evidence for PRL-8-53 comes from the original controlled study, which reported improved retention of verbal information. This remains the main reason the compound continues to attract cognitive research interest.

2. Learning Research

The original study examined acquisition and retention using verbal-learning tasks. The reported findings provide a narrow but measurable basis for investigating PRL-8-53 in memory research.

3. Cognitive-Pharmacology Research

PRL-8-53 provides an example of a compound whose early cognitive findings were promising enough to attract continued interest despite the absence of a modern development program.

4. Nootropic Research

The compound remains relevant to research into small molecules capable of influencing memory without producing broad motor-performance effects. However, the evidence base is far smaller than that of established cognitive medicines.

Dosage

The original human study used a single 5 mg oral dose of PRL-8-53. This was a small early study and does not establish a modern therapeutic dose or long-term dosing protocol.

Side Effects

The published human evidence is too limited to define a reliable long-term safety profile. The original study did not establish the safety data needed to support chronic use.

References

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Melts Brain-Fuel Dissolving Strips

Zeeshan Tariq — Thu, 01 Oct 2026 17:05:25 +0000

Buy Melts Brain-Fuel Dissolving Strips Online

Melts Brain-Fuel dissolving strips are fast-dissolving oral films formulated with paraxanthine, L-theanine, Alpha-GPC, huperzine A, vinpocetine, and B vitamins. The formulation is designed around mental alertness, focused energy, and cognitive-wellness research.

Product Information

The product is supplied as individually sealed dissolving strips intended to dissolve in the mouth without water. Its ingredient profile combines a caffeine metabolite, amino-acid derivative, choline compound, plant alkaloid, vincamine derivative, and B vitamins. The manufacturer describes the strips as a portable alternative to conventional capsules or powders.

How It Works

The formulation combines several mechanisms: paraxanthine provides adenosine-receptor activity, L-theanine is associated with relaxation and attention research, Alpha-GPC supports cholinergic signaling, and huperzine A inhibits acetylcholinesterase. B vitamins contribute to normal energy metabolism.

POTENTIAL BENEFITS

1. Mental-Alertness Research

Paraxanthine is the principal active stimulant-related component of the formulation and is studied as a caffeine metabolite with effects on adenosine signaling. This gives the strips their primary alertness-oriented research profile.

2. Focus & Attention Research

L-theanine and Alpha-GPC have both been studied in relation to attention and cognitive performance. Their inclusion creates a formulation aimed at combining alertness with a calmer cognitive profile.

3. Cholinergic Research

Alpha-GPC supplies choline for acetylcholine-related pathways, while huperzine A inhibits acetylcholinesterase. Together, these ingredients provide a clear cholinergic research component.

4. Convenient Oral Delivery

The dissolving-film format is designed for rapid oral disintegration without water. This makes the formulation portable and convenient compared with conventional tablets or capsules.

Dosage

The product is supplied as 30 individually sealed strips, but the appropriate daily use depends on the manufacturer's current product directions and the specific formulation. Because the blend contains multiple active ingredients, dosing data for individual ingredients should not be combined into a separate homemade dosing protocol.

Side Effects

Potential effects depend on the ingredients and individual sensitivity. Stimulant-related ingredients may cause jitteriness, headache, or sleep disturbance, while huperzine A and vinpocetine can produce additional pharmacological effects and drug interactions.

References

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Tesamorelin + Ipamorelin

Zeeshan Tariq — Thu, 01 Oct 2026 17:05:22 +0000

Buy Tesamorelin + Ipamorelin Online

Tesamorelin + Ipamorelin combines tesamorelin, a GHRH analogue, with ipamorelin, a selective growth hormone secretagogue. The combination is designed around two complementary mechanisms for stimulating growth hormone secretion.

Product Information

Tesamorelin has established clinical research involving GH and IGF-1 signaling, while Ipamorelin has been investigated as a selective GH secretagogue. However, there is currently no published controlled trial specifically evaluating the tesamorelin + ipamorelin combination. Evidence from each compound should therefore remain separate.

How It Works

Tesamorelin activates the GHRH pathway, while Ipamorelin activates the growth hormone secretagogue receptor. Both pathways influence pituitary GH secretion, providing the rationale for studying their combined effects.

POTENTIAL BENEFITS

1. Growth Hormone Research

Tesamorelin has demonstrated significant effects on GH and IGF-1 signaling in clinical research. Ipamorelin adds a distinct secretagogue pathway, making the combination relevant to GH-axis investigations.

2. IGF-1 Research

Tesamorelin increases circulating IGF-1 through stimulation of endogenous GH secretion. This provides a well-characterized downstream marker for research involving the GH axis.

3. Body-Composition Research

Tesamorelin has been clinically studied in relation to visceral adipose tissue and body composition. The combination with Ipamorelin is marketed around similar GH-axis research, although the combined formulation itself has not been clinically evaluated.

4. Endocrine Signaling Research

Using a GHRH analogue together with a GH secretagogue provides a model for studying how separate stimulatory signals converge on pituitary GH secretion.

Dosage

There is no established dosage for the Tesamorelin + Ipamorelin combination. Tesamorelin has been clinically studied at 2 mg once daily in its approved formulation, while Ipamorelin has separate experimental dosing data. These should not be combined into a self-directed dosing protocol.

Side Effects

GH-axis stimulation can produce headache, injection-site reactions, fluid retention, joint discomfort, and changes in glucose metabolism. Tesamorelin can also increase IGF-1, requiring monitoring in clinical use.

References

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

CJC-1295 (No DAC) + GHRP-6

Zeeshan Tariq — Thu, 01 Oct 2026 17:05:20 +0000

Buy CJC-1295 (No DAC) + GHRP-6 Online

CJC-1295 (No DAC) + GHRP-6 combines a GHRH-related peptide with a growth hormone secretagogue. The combination is designed around complementary pathways involved in stimulating growth hormone release.

Product Information

CJC-1295 No DAC is generally described as a shorter-acting GHRH analogue, while GHRP-6 activates the growth hormone secretagogue receptor. Human studies have demonstrated that GHRP-6 can strongly stimulate GH release and that GHRP-6 and GHRH can produce synergistic GH responses. However, clinical evidence for this exact CJC-1295 No DAC combination is limited.

How It Works

CJC-1295 No DAC is intended to stimulate the GHRH pathway, while GHRP-6 activates the growth hormone secretagogue receptor. These pathways can converge at the pituitary to increase GH secretion.

POTENTIAL BENEFITS

1. Growth Hormone Research

GHRP-6 has demonstrated strong GH-secretagogue activity in human research. This makes the combination relevant to experiments examining controlled stimulation of the GH axis.

2. GHRH & Secretagogue Interaction

Human studies have shown that GHRH and GHRP-6 can produce a synergistic increase in GH secretion. This provides the biological rationale for studying complementary stimulation of the two pathways.

3. IGF-1 Research

Growth hormone is an important upstream regulator of IGF-1 production. Research involving GH secretagogues therefore provides a useful model for studying downstream GH/IGF-1 signaling.

4. Pituitary-Endocrine Research

The combination allows researchers to examine interactions between GHRH signaling and secretagogue-receptor activation. This can help characterize how different GH-stimulating pathways influence pituitary responses.

Dosage

There is no established clinical dosage for CJC-1295 No DAC + GHRP-6. Human studies of GHRP-6 have used protocols including 1 microgram/kg intravenously, while clinical CJC-1295 studies have involved different formulations and doses. These component-specific protocols should not be treated as a validated dose for the combination.

Side Effects

Potential concerns include headache, flushing, appetite changes, fluid retention, and alterations in glucose or other endocrine pathways. The long-term safety profile of the exact combination remains insufficiently characterized.

References

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.